Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms 7Infections 7Prostatic Neoplasms 4Neutropenia 4Lymphoma 4Leukemia 4Neoplasms, Plasma Cell 3Febrile Neutropenia 3Urinary Tract Infections 2Pancreatic Neoplasms 2Pancreatic Cyst 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Staphylococcal Infections 1Squamous Cell Carcinoma of Head and Neck 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Recurrence 1Rectal Neoplasms 1Pulmonary Arterial Hypertension 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pain 1

Interventions

Cyclophosphamide 328Methotrexate 182Cytarabine 164fludarabine phosphate 151Vincristine 128Dexamethasone 126fludarabine 123Peripheral Blood Stem Cell Transplantation 116Whole-Body Irradiation 108Etoposide 106Mycophenolic Acid 105Tacrolimus 95Busulfan 95Filgrastim 93Melphalan 81Cyclosporine 80Rituximab 79Doxorubicin 79Mercaptopurine 70Radiotherapy 62Antilymphocyte Serum 62Prednisone 57Granulocyte Colony-Stimulating Factor 57blinatumomab 55pegaspargase 54Asparaginase 54Thiotepa 52Daunorubicin 52Calcium Dobesilate 47Clofarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Ciprofloxacin × Clear all
NCT07016165 2025-08-22

Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

Gadjah Mada University

Phase 4 Recruiting
120 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡